Cargando…
PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8(+) T cells in hematogenous metastasis model with lymphocyte infusion
Brain metastases are common complication in cancer patients. Immune checkpoint inhibitors show therapeutic benefits also in patients with central nervous system (CNS) metastases. However, their antitumor effects on metastatic tumors and their underlying mechanisms are still poorly understood. In thi...
Autores principales: | Masuda, Chinami, Morinaga, Mamiko, Wakita, Daiko, Yorozu, Keigo, Kurasawa, Mitsue, Sugimoto, Masamichi, Kondoh, Osamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971192/ https://www.ncbi.nlm.nih.gov/pubmed/34797455 http://dx.doi.org/10.1007/s10585-021-10135-6 |
Ejemplares similares
-
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
por: Masuda, Chinami, et al.
Publicado: (2019) -
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies
por: Iwai, Toshiki, et al.
Publicado: (2018) -
Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022) -
Anti-VEGF Antibody Protects against Alveolar Exudate Leakage Caused by Vascular Hyperpermeability, Resulting in Mitigation of Pneumonitis Induced by Immunotherapy
por: Iwai, Toshiki, et al.
Publicado: (2021) -
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)